Loading…
← CockpitCompetitor Analysis › IMCR Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 ShOpen in the cockpit ↗

Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 ShIMCRCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops bispecific T-cell receptor (TCR) therapies for cancer, led by approved treatment Kimmtrak for melanoma.

Momentum weak 28
Mkt cap
$1.44B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$14.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 8.3%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$27.51
1D-1.1%
1W-13.1%
1M-15.6%
3M-24.2%
6M-6.9%
YTD-20.7%
1Y-24.8%
ATR %5.2%
Beta0.63
52w lowhigh32.4% off high

What Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh does

Develops bispecific T-cell receptor (TCR) therapies for cancer, led by approved treatment Kimmtrak for melanoma.

Earns most of its revenue from Kimmtrak, an infusion approved in 2022 for uveal melanoma (an eye cancer), but only for patients with a particular tissue type, which limits who can be treated. The rest of the pipeline, including drugs aimed at the PRAME cancer marker, is still in trials.

Products and services

  • Kimmtrak (tebentafusp, uveal melanoma)
  • TCR pipeline in other solid tumors and infectious disease

Customers

  • Oncologists/cancer centers

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • TCR bispecific immunotherapy

What could go right

  • Kimmtrak revenue growth and label expansion
  • Platform-driven pipeline diversification

What could go wrong

  • Niche uveal melanoma market size
  • Clinical trial failure risk for pipeline

Moat: narrow (IP / patents, process know-how). Proprietary ImmTAC bispecific TCR platform behind the first approved TCR therapeutic, hard to replicate.

Headquarters: Oxfordshire, UK · Founded: 2008 · Employees: 524

Named competitors

Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh at a glance

Size Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh (IMCR) is a United States Health Care company (Biotechnology) with a market value of $1.44B, the 1995th largest of 3,085 United States companies the cockpit tracks. Shares closed at $27.51 on 18 Nov 2026.

Performance Over six months the shares fell 6.9%, against -20.3% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 20 in its peer set.

Growth Revenue grew 13.0% over the last twelve months (peer median +26.4%); the operating margin is -6.8% (peer median -295.1%).

Valuation It trades at 2.3× enterprise value to sales against a peer median of 26.5× (cheapest of 17).

Credit Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh has 1 bond outstanding ($402M).

Short interest Short interest is 15.1% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026IMCR 92Peer median 79
Six months, rebased to 100: Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh against the median of its 20 peers (local-currency closes).

Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$429M$401M$310M$250M$177M
Revenue growth—+29%+24%+41%—
Gross profit$420M$393M$303M$245M$169M
EBITDA-$25.1M-$42.2M-$66.3M-$55.8M-$56.4M
Net income-$32.1M-$35.6M-$51.1M-$55.5M-$50.8M
Free cash flow-$18.3M-$15.1M$20.9M-$2.49M-$38.6M
Capital expenditure$7.80M$4.35M$5.18M$5.45M$2.71M
Total debt$436M$437M$433M$84.0M$83.4M

Quarterly statements and history in the cockpit →

Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-25%0%+25%+50%688105QURE688765ABSIURGN2637ANABRAPPMSB0870106881854588KRSAPGENIMCR6-month return →1-month return →
Up and to the right = strong over both horizons. Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%0×500×1,000×688105QURE688765ABSIURGNMSB0870104588KRSAPGENIMCRRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh is the large dot.

Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh competitors and peer comparison

Head to head with its named competitors (IMCR vs BMY vs RO.SW)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR$1.44B-7%+13%-7%2.3×n/a
Bristol Myers Squibb BMY$122B+3%+4%33%3.1×-13.1%
Roche RO.SW$381B+21%-1%31%5.7×1.7%

How Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh against its 20 peers (data as of 18 Nov 2026)
MeasureIMCRPeer medianRank in peer set
1-month return-15.6%-10.2%8th lowest of 21
6-month return-6.9%-20.3%8th highest of 20
Distance from 52-week high-32.4%-47.0%3rd highest of 21
Revenue growth (TTM)+13.0%+26.4%6th lowest of 17
Operating margin-6.8%-295.1%7th highest of 18
EV / Sales2.3×26.5×cheapest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%2.3×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%4.9×39.4%-2.5%
uniQure QUREUnited States$1.42B-17%+28%-1,027%65.4×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%205.0×n/an/a
Absci ABSIUnited States$1.41B+65%-47%-9,155%835.7×n/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%6.3×n/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%n/an/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%7.9×0.5%+25.6%
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%50.1×n/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%12.8×n/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%359.6×n/an/a
CanSino Biologics 688185.SSChina$1.38B0%+30%-4%6.6×n/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%408.9×n/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%21.3×n/an/a
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.51B-37%+12%8%13.1×n/an/a
Korsana Biosciences KRSAUnited States$1.52B+54%-64%-5,277%1,058.7×n/an/a
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a
Precigen PGENUnited States$1.53B0%+2,388%21%10.1×n/an/a
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%31.7×n/an/a

Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh bonds and credit

Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh has 1 bond outstanding with $402M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh's main competitors?
Named competitors: Bristol Myers Squibb (BMY), Adaptimmune (private or unlisted), Roche (RO.SW). The cockpit's measured peer set (industry) also includes Nanjing Vazyme Biotech (688105.SS), uniQure (QURE), Wuhan Healthgen Biotechnology (688765.SS), Absci (ABSI), UroGen Pharma (URGN), Fujian Haixi Pharmaceuticals (2637.HK).
Is Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh expensive compared with its peers?
On ev / sales it trades at 2.3× against a peer median of 26.5×, cheapest of 17 in its peer set.
How has Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh stock performed?
Over six months to 18 Nov 2026 the shares returned -6.9% against -20.3% for the median peer; over one year -24.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.